Table 3.
Univariate and multivariate analyses of prognostic factors related to relapse-free survival.
| Prognostic marker | Events/patients (n) | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | pa | HR | 95% CI | pa | ||
| pN | 0.056 | ||||||
| pN− | 6/25 | 1 | |||||
| pN+ | 13/26 | 2.47 | 0.94–6.51 | ||||
| HER2 expression (TR-FRET) | 0.003 | 0.003 | |||||
| <8,500 receptors/cell | 9/36 | 1 | 1 | ||||
| ≥8,500 receptors/cell | 10/15 | 3.93 | 1.59–9.72 | 3.93 | 1.59–9.72 | ||
| HER2 expression (IHC) | 0.043 | ||||||
| 0 | 12/40 | 1 | |||||
| 1+/2+ | 7/11 | 2.78 | 1.09–7.10 | ||||
HER2 expression levels measured by TR-FRET were dichotomised in the low and moderate expression groups according to the cut-off value derived from the ROC curve for predicting disease recurrence or metastases. The optimal cut-off value was 8,500 receptors per cell (sensitivity = 52.63%, specificity = 84.38%).
aLikelihood-ratio test.